Series B · Biotech · Hafnarfjörður, Iceland · Founded 2018 · 51–200 employees
Coripharma operates as a specialized European Contract Development and Manufacturing Organisation focused on technically challenging generic pharmaceuticals and solid oral dosage forms. The company's manufacturing facility is notable for being powered entirely by local geothermal and hydropower renewable energy sources. Established following a management-led acquisition of a former Actavis plant from Teva Pharmaceuticals, the company has since scaled its operations significantly. In April 2023, Coripharma secured a major ten million euro funding round backed by Icelandic institutional investors to fuel its continued growth.
No open roles listed right now.